NOVARTIS AG Vs. WINDLAS BIOTECH PVT LTD

JUDGEMENT

(1.) This hearing has been done through hybrid mode.

(2.) Submissions have been heard in respect of the applications filed on behalf of the Plaintiffs.

(3.) The present three suits have been filed seeking permanent injunction restraining the infringement of Indian Patent No.IN229051 (hereinafter, "suit patent"), damages, rendition of accounts, delivery up, etc. As per the Plaintiffs, the suit patent relates to a pharmaceutical composition consisting of Valsartan or a pharmaceutically acceptable salt thereof, and Sacubitril or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The said pharmaceutical preparation is used in the treatment of cardiovascular disease.